跳至主要内容
临床试验/NCT01001988
NCT01001988已完成3 期

Long-term Follow-up of Immunogenicity of a Single Dose of JE-CV in Toddlers in Thailand and the Philippines

Sanofi Pasteur, a Sanofi Company4 个研究点 分布在 2 个国家目标入组 596 人开始时间: 2009年8月7日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
入组人数
596
试验地点
4
主要终点
Percentage of Participants With Japanese Encephalitis Seroprotection Following a Single Dose of JE-CV

研究概览

简要总结

This is a long-term follow-up of the persistence of immune response in participants who previously received a single dose of JE-CV at age 12 to 18 months in Study JEC02 (NCT00735644) . No vaccination was administered during the present long-term follow-up study.

Primary Objective:

  • To describe the yearly persistence of humoral immune response to Japanese encephalitis after a single dose of JE-CV

详细描述

Persistence of immune response will be determined in participants who previously received a single dose of JE-CV at age 12 to 18 months in Study JEC02 (NCT00735644). No vaccination will be given in this study.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Prevention
盲法
None

入排标准

年龄范围
2 Years 至 3 Years(Child)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Percentage of Participants With Japanese Encephalitis Seroprotection Following a Single Dose of JE-CV

时间窗: Day 0 (pre-vaccination) from study JEC02, Day 28 post-vaccination from study JEC02, and at Years 1, 2, 3, 4, and 5 post-vaccination

Seroprotection was defined as the proportion of participants with Japanese encephalitis virus neutralizing antibody titers ≥10 1/dil as measured by a JE 50% plaque reduction neutralization test (PRNT50).

Summary of Geometric Mean Titers of Japanese Encephalitis Virus Antibodies Following a Single Dose of a JE-CV

时间窗: Day 0 (pre-vaccination) from JEC02, Day 28 post-vaccination from JEC02, and at Years 1, 2, 3, 4, and 5 post-vaccination

Geometric mean titers of Japanese encephalitis virus antibodies were assessed using the PRNT50 test.

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验

终止
不适用
A Follow up Study of Group B Streptococcus (GBS)-NN/NN2 Vaccine in Healthy VolunteersGroup B Streptococcus Infection
NCT06280157Minervax ApS29
已完成
4 期
A Study to Evaluate Persistence of Immune Responses After Post-exposure Prophylaxis of Rabipur® (Purified Chicken-embryo Cell Rabies Vaccine) in Chinese ChildrenVirus Diseases
NCT02991872GlaxoSmithKline150
进行中(未招募)
不适用
Follow-up study to evaluate the long-term immunogenicity and safety ofGlaxoSmithKline Biologicals' HPV (580299) vaccine in healthy femalesubjects.
EUCTR2009-011357-41-DEGlaxoSmithKline Biologicals667
进行中(未招募)
不适用
A long-term, open, follow-up of the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV-16/18 L1 VLP AS04 vaccine in healthy female subjects up to 10 years after administration of the first vaccine dose in study HPV 014. - HPV-060 EXT 014 Y5-10For active immunization of women from the age of 10 years onwards to prevent cervical cancer (squamous-cell carcinoma and adenocarcinoma) by protecting against incident and persistent infections, cytological abnormalities including atypical squamous cells of undetermined significance (ASC US) and cervical intraepithelial neoplasia (CIN), CIN1 and pre-cancerous lesions (CIN2 and CIN3), caused by oncogenic human papillomavirus (HPV) types 16 and 18.
EUCTR2009-011357-41-PLGlaxoSmithKline Biologicals667
进行中(未招募)
不适用
A long-term, open follow-up of the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV-16/18 VLP/AS04 vaccine in healthy female subjects up to 10 years after administration of the first vaccine dose in study HPV-013. - HPV-025 EXT 013For the prevention of high-grade cervical intraepithelial neoplasia (CIN grades 2 and 3) and cervical cancer causally related to human papillomavirus (HPV) types 16 and 18.
EUCTR2008-000369-44-DEGlaxoSmithKline Biologicals600